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Osteosarcoma incidence patterns suggest an aetiologic role for perinatal factors, and growth and development. Osteosarcoma
patients (n¼158) and controls with benign orthopaedic conditions (n¼141) under age 40 were recruited from US orthopaedic
surgery departments. Exposures were ascertained by interview, birth, and growth records. Age- and sex-adjusted odds ratios (OR)
and 95% confidence intervals (CI) were estimated. Current height and age- and sex-specific height percentiles were not associated
with osteosarcoma risk. Male cases, however, appeared to have an earlier adolescent growth period, and earlier attainment of final
height (OR¼7.1; 95% CI¼1.6–50 for o19 vs 19þ years), whereas earlier puberty appeared protective with ORs of 0.41 (95% CI
0.18–0.89) and 0.68 (95% CI 0.31–1.5) for developing facial and pubic hair, respectively. High birth weight was associated with an
elevated osteosarcoma risk (OR¼3.9; CI¼1.7–10 for 4000g vs 3000–3500g), although there was no trend in risk with increasing
weight. These data provide some evidence that osteosarcoma is related to size at birth and in early adolescence, while earlier puberty
in male subjects may be protective.
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There are few established osteosarcoma risk factors apart from
early exposure to high-dose radiation, and Paget’s disease,
hereditary retinoblastoma, and Li–Fraumeni Syndrome (Miller
et al, 1996). The bimodal age–incidence curve reflecting peak rates
occurring both in adolescence and in older age suggests two
separate aetiologies. Enhanced carcinogenic susceptibility during
the adolescent growth period is suggested by higher radiogenic
bone cancer risk among children than adults, and the character-
istic development of childhood tumours in the long bone
epiphyses of the lower limbs (Fraumeni, 1967). An excess
osteosarcoma risk in larger compared with smaller dog breeds
may be consistent with this hypothesis (Withrow et al, 1991).
Higher male than female incidence rates in puberty, and the early
age at which osteosarcoma incidence first peaks – 10–14 years
of age in girls, and 15–19 years in boys – may indicate the
importance of accelerated growth and hormonal differences, and
raise the possibility that very early-life exposures play a role as well
(SEER, 2005).
In this study, we focused on the associations of osteosarcoma
with factors related to growth and development from the in utero
period through puberty and adolescence.
MATERIALS AND METHODS
Study population
Participants were drawn from orthopaedic surgery departments
in 10 US medical centres between 1994 and 2000 (Massachusetts
General Hospital, Boston, MA, USA; Creighton University/St
Joseph’s Hospital and University of Nebraska, Omaha, NE, USA;
Children’s National Medical Center and Washington Hospital
Center, Washington, DC, USA; University of Chicago and Rush
Presbyterian St Luke’s, Chicago, IL, USA; University of Florida,
Gainesville, FL, USA; University of California, Los Angeles, CA,
USA; Cleveland Clinic, Cleveland OH, USA). Cases were patients
with newly diagnosed primary osteosarcoma admitted for evalua-
tion of eligibility for limb salvage surgery. Controls were
orthopaedic patients from the same departments with benign
tumours (26%), or non-neoplastic conditions such as inflamma-
tory diseases, cysts, and trauma (ICD-9-CM codes 289.1, 277.8,
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y354.0, V711, 682.6, 714.3–756.59, 810.0–885.0, and 959.7). Nurse
coordinators were responsible for control selection by identifying
the next patient matching the case on age (þ/ 5 years), sex,
hospital, and distance from the respective medical centre based on
the participant’s residential zip code. Pathology reports from
surgery and/or biopsy were obtained for all cases and for controls
for whom this documentation was applicable to confirm diagnosis,
whereas hospital medical records confirmed diagnoses for controls
without a pathology report (with conditions such as injury,
reconstruction, revision, or pain).
Institutional review boards at each of the medical centres
approved this study, and informed consent, which included a
check list for a questionnaire, blood draw, and toenail collection,
was obtained from all participants. Of eligible cases, 13.6% were
not enrolled and a further 3% declined to participate in any of the
study components. Of those enrolled in the study, 93.5% of cases
and 98% of controls completed interviews. Reasons for non-
participation in the questionnaire component included refusal,
death, extreme illness following surgery and failure to return for
follow-up care. The present analysis was restricted to 169 cases and
144 controls less than 40 years of age to focus on the aetiology of
the adolescent-young adult peak in osteosarcoma incidence.
Exposure and covariate information
Interviews ascertaining information on growth and development,
physical activity, and medical history were conducted in the
hospital, clinic, or ward with cases after surgery, and after surgery,
or other therapy in controls. A supplemental interview on
pregnancy exposures was conducted with parents of participants
less than 20 years of age, whereas participants over 20 were asked
directly.
Participants 9–21 years of age were asked to give consent for
growth records acquisition. Of 109 cases and 91 controls,
respectively, all of the 78 (71.5%) and 57 (62.6%) participants
who reported a regular health-care provider gave permission for
contact, and a total of 402 growth records were obtained for 49
cases and 46 controls (average of 4.2 records per participant).
Growth records validated participants’ self-reports of height
(shorter, about the same, and taller) compared with their peers
at various ages. Among the combined cases and controls, mean
height from records was 9% lower and 1.5% higher among
participants who reported being shorter and taller, respectively,
compared with being about the same height as their peers at age 9
or 10. Similarly, recorded height was 7% lower and 4.5% higher at
age 12 or 13, and 3.5% lower and 6% higher at age 15 or 16. Results
were similar when evaluated separately for cases and controls.
US born participants were asked for their consent to acquire
birth records from state vital records offices with 97% (n¼154)
of cases and 99% (n¼139) of controls providing permission.
For states where at least six participants were born records were
obtained for a total of 289 participants. Equal proportions of cases
(55%; n¼87) and controls (55%; n¼78) were missing information
in the birth records for pregnancy length. Pregnancy complications
were missing for 54% (n¼85) of cases and 59% (n¼83) of
controls, and of those with these data, complications were rare
(two cases/five controls). Birth weight as reported by the
participant or mother (mean¼3392; s.d.¼589) and from records
(mean¼3389; s.d.¼556) were highly correlated in those with both
sources of information (r¼0.95; n¼176). Therefore, reported
birth weight was used when birth records were unavailable.
Statistical analysis
Current height for all participants was converted to percentiles
based on sex- and age-specific growth standards provided by the
National Center for Health Statistics (CDC, 2000). Unconverted
height was analysed in participants 21 years of age or older who
were assumed to have attained their final height. Tertiles were
based on sex-specific distributions in the control group. Birth
weight percentiles were based on gestational age and sex (Oken
et al, 2003) and quartiles were based on the control distribution.
Unconditional logistic regression models including age and sex
were used to estimate odds ratios (OR) and 95% confidence
intervals (CI). Analyses were based on male and female subjects
combined to increase the sample size but are presented separately
when findings differed by sex. Further inclusion of study centre,
geographic ring, education, and family income did not affect the
estimates. Linear trends were assessed using orthogonal poly-
nomial contrasts (Winer, 1962) or by including the continuous
variable in the model. The data analysis was generated using SAS/
STAT software (1999).
RESULTS
Similar proportions of cases (64%) and controls (62%) were under
20 years of age, and they were comparable in sex and race/ethnicity
(Table 1). Cases had a lower combined family income. There were
no trends in age- and sex-adjusted osteosarcoma risk with
increasing participant’s education, or with mother’s or father’s
education (data not shown).
Neither height percentile nor absolute height was associated
with osteosarcoma risk (Table 2). In participants 21–39 years of
age, attaining final height at a younger age was associated with a
reduced risk in female subjects (OR¼0.53; CI¼0.15–1.8 for o17
vs 17þ years), but with an elevated risk in male subjects (OR¼7.1
Table 1 Distributions of characteristics for osteosarcoma cases and
controls
Cases (n¼158) Controls (n¼141)
No. (%)
a No. (%)
a
Age (y)
0–9 8 (5.1) 9 (6.4)
10–14 37 (23.4) 21 (14.9)
15–19 56 (35.4) 58 (41.1)
20–24 28 (17.7) 19 (13.5)
25–29 12 (7.6) 19 (13.5)
30–34 10 (6.3) 7 (5.0)
35–39 7 (4.4) 8 (5.7)
Sex
Male 85 (53.8) 74 (52.5)
Female 73 (46.2) 67 (47.5)
Race
White 130 (82.3) 114 (80.9)
Black 14 (8.9) 15 (10.6)
Other 14 (8.9) 12 (8.5)
Income
o$40000 68 (43.0) 39 (27.7)
$40000–60000 31 (19.6) 33 (23.4)
4$60000 34 (21.5) 57 (40.4)
Missing 25 (15.8) 12 (8.5)
Participant’s education
Less than H.S. 90 (57.0) 70 (49.7)
H.S. or equivalent 26 (16.5) 24 (17.0)
Some college 26 (16.5) 24 (17.0)
College or post-grad 15 (9.5) 23 (16.3)
Missing 1 (0.6) 0 (0.0)
H.S.¼high school; y¼year.
aPercentages do not add to 100 because the variable is
presented for a subgroup of cases and controls or because of rounding.
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association of participant’s height percentile with risk showed no
consistent pattern in any subgrouping according to mother’s
height (data not shown).
Cases appeared less likely to be shorter than their peers at ages
9–10 and 12–13, and more likely to be taller at ages 15–16,
compared with being about the same height (Table 2). The reduced
ORs for being shorter at younger ages were consistent in male and
female subjects, but the elevated OR for being taller at age 15–16
resulted from an OR of 2.4 in male subjects and 1.0 in female
subjects. Among male subjects, controls were more likely than
cases to have started shaving, and developing pubic hair early
in male controls followed a similar pattern (Table 3). Age at
menarche was not associated with risk. Results for the puberty
variables were unchanged with adjustment for height percentile
(data not shown).
There was no consistent association between sports participa-
tion at various ages during childhood and osteosarcoma risk (data
not shown). Comparing frequent with less frequent activity (4þ/
week vs o4/week), the OR were generally elevated in female
subjects, in particular, at ages 15 or 16 (OR¼2.9; CI¼1.2–7.4),
whereas there was no association in male subjects (data not
shown). Excluding controls whose condition on study entry was
fracture attenuated the elevated estimate for more frequent activity
in female subjects (OR¼1.8; CI¼0.8–4.6).
Excluding controls whose condition on study entry was a
fracture or fibroma, the OR for ever fracturing a bone was 0.68
(CI¼0.41–1.1); with further exclusion of fractures occurring
within 2 years of questionnaire completion the OR was 0.65. The
site of prior fracture was examined to identify whether for any
case, the tumour occurred in the same bone; they matched in only
two cases (within 1 year and 15 years of diagnosis).
Diagnostic or therapeutic radiation before the present illness
was not associated with osteosarcoma risk (OR¼1.2; CI¼0.75–
1.9). Radiation exposure was mainly in the form of routine medical
X-rays (88% of cases and 87% of controls).
High birth weight was associated with an increased osteosarcoma
risk (Table 4) that was similar when stratified by age o21 vs
21þ years (data not shown), but stronger among female subjects
(OR¼7.2; CI¼1.7–50) than male subjects (OR¼2.9; CI¼1.0–
9.1). There was no trend in risk with gestational age (P¼0.63), and
adjustment for gestational age did not change the OR for birth
weight. Birth weight percentiles confirmed the increased risk
among heavy babies (highest vs lowest quartile OR¼4.6; 95%
CI¼1.4–16.4). Longer birth length appeared protective though the
association was not linear or statistically significant. The estimates
for both birth weight and length were slightly stronger with mutual
adjustment (OR¼7.6 for birth weight 44000g vs 3000–3500g;
OR for birth length¼0.40, 0.32, and 0.34 for 20, 21, and 22þ
inches, respectively, vs o20 inches). There were no associations
Table 2 Age- and sex-adjusted ORs and 95% CIs for participant’s and
parent’s height and osteosarcoma risk
Cases (n¼158) Controls (n¼141) OR
a 95% CI
a
No. (%)
b No. (%)
b
Current height (percentile)
o51 57 (36.1) 47 (33.3) 1.0
51–81 43 (27.2) 45 (31.9) 0.78 (0.44–1.4)
481 56 (35.4) 47 (33.3) 0.95 (0.54–1.7)
Current height (tertiles)
c
Lowest 14 (8.9) 15 (10.6) 1.0
Middle 16 (10.1) 16 (11.3) 1.1 (0.40–3.0)
Highest 17 (10.8) 18 (12.8) 1.0 (0.38–2.7)
Height comparison to peers at age 9 or 10
d
Shorter 27 (17.1) 36 (25.5) 0.56 (0.30–1.0)
About the same 74 (46.8) 57 (40.4) 1.0
Taller 52 (32.9) 41 (29.1) 0.98 (0.57–1.7)
Height comparison to peers at age 12 or 13
e
Shorter 27 (17.1) 33 (23.4) 0.66 (0.35–1.2)
About the same 64 (40.5) 52 (36.9) 1.0
Taller 47 (29.7) 43 (30.5) 0.88 (0.51–1.5)
Height comparison to peers at age 15 or 16
f
Shorter 24 (15.2) 26 (18.4) 1.0 (0.53–2.0)
About the same 52 (32.9) 58 (41.1) 1.0
Taller 36 (22.8) 25 (17.7) 1.6 (0.86–3.1)
Mother’s height (cm)
o162.0 57 (36.1) 36 (25.5) 1.0
162.0–167.6 66 (41.8) 67 (47.5) 0.59 (0.34–1.0)
4167.6 31 (19.6) 38 (27.0) 0.49 (0.26–0.92)
Father’s height (cm)
o175.3 62 (39.2) 48 (34.0) 1.0
175.3–180.3 34 (21.5) 43 (30.5) 0.63 (0.35–1.1)
4180.3 56 (35.4) 47 (33.3) 0.89 (0.51–1.5)
aOR¼odds ratio; CI¼confidence interval.
bPercentages do not add to 100 because
of either missing data or the variable is presented for a subgroup of cases and
controls.
cAmong participants 21+ years of age; tertile cutpoints for male subjects
are 177.8 and 182.9cm and for female subjects are 162.6 and 170.2cm.
dAmong
participants 9+ years of age.
eAmong participants 12+ years of age.
fAmong
participants 15+ years of age.
Table 3 Age- and sex-adjusted ORs and 95% CIs for development
measures and osteosarcoma risk
Cases (n¼158) Controls (n¼141) OR
a 95% CI
a
No. (%)
b No. (%)
b
Reached menarche
c
No 8 (5.1) 8 (5.7) 1.0
Yes 65 (41.1) 59 (41.8) 1.5 (0.46–5.2)
Age at menarche (y)
d
o12 17 (10.8) 14 (9.9) 1.0 (0.39–2.7)
12 18 (11.4) 16 (11.3) 1.0 (0.40–2.7)
13 19 (12.0) 17 (12.1) 1.0
14+ 11 (7.0) 12 (8.5) 0.85 (0.29–2.5)
Started shaving
e
No 33 (20.9) 16 (11.3) 1.0
Yes 52 (32.9) 53 (37.6) 0.41 (0.18–0.89)
Age first shaved (y)
f
o15 10 (6.3) 20 (14.2) 1.0
15 21 (13.3) 13 (9.2) 3.2 (1.1–9.1)
16 15 (9.5) 9 (6.4) 3.1 (1.0–10)
17+ 6 (3.8) 11 (7.8) 0.99 (0.27–3.5)
Developed pubic hair
e
No 23 (14.6) 15 (10.6) 1.0
Yes 62 (39.2) 58 (41.1) 0.68 (0.31–1.5)
Age first developed pubic hair (y)
g
o13 18 (11.4) 22 (15.6) 0.65 (0.28–1.5)
13 28 (17.7) 22 (15.6) 1.0
14+ 16 (10.1) 14 (9.9) 0.90 (0.36–2.2)
aOR¼odds ratio; CI¼confidence interval; y¼year.
bPercentages do not add to 100
because of either missing data or the variable is presented for a subgroup of cases
and controls.
cAmong female subjects.
dAmong female subjects who have reached
menarche.
eAmong male subjects.
fAmong male subjects who have started to shave.
gAmong male subjects who have developed pubic hair.
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intake during pregnancy and father’s smoking during pregnancy
(data not shown).
DISCUSSION
Osteosarcoma appears to be positively associated with bone
growth, based primarily on the rapid rise and fall of incidence
rates from adolescence into young adulthood, and buttressed by
the typical occurrence of this tumour (approximately 70% (Miller
et al, 1996)) in the long bone epiphyses and the strong positive
association in canines with breed size (Withrow et al, 1991), and in
particular, height (Ru et al, 1998).
Findings for growth and development in human populations,
however, are equivocal. There is some evidence (Fraumeni 1967;
Gelberg et al, 1997; Cotterill et al, 2004) of cases being taller than
controls, although the differences often derive from inconsistent
subgroup findings defined by age, gender, or anatomic site. Other
data suggest no differences in height or average growth rate
(Operskalski et al, 1987; Pui et al, 1987; Glasser et al, 1991; Buckley
et al, 1998). Our data show no association with height, but suggest
that cases are less likely to be shorter than their peers before and
during the early years of adolescent growth. The positive
association we observed with birth weight may also be consistent
with earlier growth being adverse. The few previous studies of
birth size, like those of height, have had conflicting results
(Operskalski et al, 1987; Gelberg et al, 1997; Buckley et al, 1998).
The increased risk we observed in the lowest birth length category
when adjusted for birth weight could be a chance finding given the
lack of overall trend, the increased risk with elevated birth weight,
and the inconsistent findings from prior studies (Operskalski et al,
1987; Gelberg et al, 1997). However, our estimate is similar to that
of an earlier study (RR for 21.5 vs 19.5–20.5 inches¼0.59)
(Operskalski et al, 1987).
The development of secondary sexual characteristics has also
been a focus of studies of growth and development in relation to
osteosarcoma risk (Gelberg et al, 1997; Buckley et al, 1998). We
found no associations among female subjects, but earlier devel-
opment of facial and pubic hair appeared protective in male
subjects. Like the growth data, previous findings are inconsistent
with respect to timing of sexual development (Gelberg et al, 1997;
Buckley et al, 1998).
Together with those of earlier studies, our results may suggest
that there is an underlying relationship of growth and maturation
patterns with osteosarcoma risk that is likely too weak to explain a
meaningful portion of the remarkable age–incidence curve. The
shape of this curve, instead of resulting from growth character-
istics, may simply be a weakly correlated marker of the true
aetiologic event. The abrupt rise and decline in incidence would be
consistent with exposure occurring at a specific common time
before the peak. Because of the young age of cases, and resultant
requirement for a short common exposure interval, the period
during in utero development seems likely. In fact, the age–
incidence curve is similar to that of vaginal clear-cell adenocarci-
noma, caused by in utero diethylstilbestrol exposure. In that
malignancy, the teratogenic/carcinogenic error occurs in the
foetus, but is not manifest until the normal hormonal development
and maturation of the reproductive system following puberty.
Similarly, carcinogenic events related to in utero bone develop-
ment may only become manifest during their major development
and maturation in adolescence. We saw no evidence of adverse
effects of in utero exposure to alcohol or tobacco. Given the above
discussion of growth patterns, perhaps the most likely intrauterine
exposures are those with independent effects on subsequent
growth and development. Prime candidates for consideration
might be gene variants responsible for foetal bone development,
and/or environmental exposures such as nutritional factors or
infections.
Another commonly suggested risk factor for osteosarcoma is
prior bone trauma, although epidemiologic studies have not found
evidence of an association with the exception of one study
(Operskalski et al, 1987). We attempted to assess this based on
histories of prior fractures, and by frequency of sports participa-
tion although neither was associated with excess risk, and prior
fracture was associated with decreased risk. Excluding conditions
for which prior fractures or other trauma might be a risk factor
did not alter our results, but residual bias is possible. However,
because only one case reported a fracture of the same bone more
than a year before the diagnosis of osteosarcoma, if such trauma
were a risk factor, it would seem to account for only a very small
portion of disease.
This investigation has several strengths, including a high
cooperation rate with an in-person interview conducted by trained
interviewers, and a control group of orthopaedic patients,
minimising the opportunity for selection bias, particularly for
early-life exposures. There are several limitations as well. The
case series included only those patients commonly treated by
orthopaedic surgeons (those with limb tumours), with other
sites underrepresented, for example, skull, jaw, rib, and
vertebral column. Because the hospitals are academic centres with
a high rate of referral patients, the opportunity for referral bias
exists. For this reason we stratified the controls to the distribution
of cases according to hospital, and residential distance from the
hospital. Risk estimates were virtually unchanged with adjustment
for these variables, as well as for family income. The use of
orthopaedic controls has potential disadvantages as well. If the
factors we investigated are associated with risk for orthopaedic
conditions as well as osteosarcoma, we might fail to identify
differences. To mitigate this possibility we included a wide variety
of diagnoses in the control group. Finally, the relatively small
number of cases limited statistical power, however, owing to the
rarity of this tumour, our study includes more cases than all but
one of previously published studies (Cotterill et al, 2004). Larger
studies, however, are needed, particularly to investigate subgroup
risks.
Table 4 Age- and sex-adjusted ORs and 95% CIs for pregnancy and
birth characteristics and osteosarcoma risk
Cases (n¼158) Controls (n¼141) OR
a 95% CI
a
No. (%)
b No. (%)
b
Participant’s birth order
First 72 (45.6) 63 (44.7) 1.0
Second or later 81 (51.3) 74 (52.5) 0.97 (0.61–1.5)
Gestational age reported by participants
Earlier 38 (24.1) 37 (26.2) 0.90 (0.51–1.6)
On time 76 (48.1) 67 (47.5) 1.0
Later 36 (22.8) 30 (21.3) 1.0 (0.58–1.9)
Birth weight (g)
o3000 28 (17.7) 27 (19.1) 1.3 (0.66–2.5)
3000–3499 48 (30.4) 58 (41.1) 1.0
3500–3999 41 (25.9) 37 (26.2) 1.3 (0.73–2.4)
4000+ 27 (17.1) 8 (5.7) 3.9 (1.7–10)
Birth length (inches)
o20 32 (20.3) 16 (11.4) 1.0
20 18 (11.4) 18 (12.8) 0.54 (0.21–1.3)
21 44 (27.8) 45 (31.9) 0.51 (0.24–1.1)
22+ 19 (12.0) 12 (8.5) 0.83 (0.31–2.2)
aOR odds ratio; CI confidence interval.
bPercentages do not add to 100 in some cases
because of missing data.
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studies do not suggest a clear growth and development pattern
that could explain the dramatic young-age peak of this
malignancy. However, there are enough signals to speculate that
growth and development characteristics may be markers of
true aetiologic events to which they are weakly correlated.
Given the sharpness of the young incidence peak, the most
likely timing of these events is in-utero development.
A more concerted effort to evaluate this aspect of aetiology is
warranted.
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